Xuebijing injection mitigates instant blood−mediated inflammatory reaction and enhances intrahepatic islet transplantation via target NF−κB pathway
This study provides the evidence that XBJ improves islet transplantation outcomes through dual mechanisms targeting the IBMIR. As an already approved drug, XBJ presents a promising and readily translatable adjunctive therapy for clinical intrahepatic islet transplantation.
Authors
- J. M. Yang
- Jiaqi Zou (ORCID: https://orcid.org/0000-0002-9385-2856)
- Tengli Liu
- MD Yijun Zhang
- Xiaoyan Hu (ORCID: https://orcid.org/0000-0001-8825-4571)
- Xuejie Ding (ORCID: https://orcid.org/0000-0003-4572-2149)
- Yingyi Qi
- Tianyi You
- Rui Yang (ORCID: https://orcid.org/0000-0002-7733-0636)
- Boya Zhang (ORCID: https://orcid.org/0000-0002-8868-0391)
- Yan Wang (ORCID: https://orcid.org/0000-0003-2057-0097)
- Rui Liang (ORCID: https://orcid.org/0009-0004-6748-5142)
- Qing Liu
- Yixiang Zhan
- Zhuzeng Yin
- Na Liu
- Zhaoce Liu
- Peng Sun
- Yuqi Chen
- Xiangheng Cai
- Tingsheng Jiang
- Shusen Wang
Institutions
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.3389/fimmu.2025.1671966
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00